Platinum Resistant Clinical Trials

1 recruiting

Platinum Resistant Trials at a Glance

5 actively recruiting trials for platinum resistant are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 1 with 3 trials, with the heaviest enrollment activity in Detroit, Los Angeles, and Buffalo. Lead sponsors running platinum resistant studies include Whitehawk Therapeutics, Inc., AbbVie, and Outpace Bio, Inc..

Browse platinum resistant trials by phase

Treatments under study

About Platinum Resistant Clinical Trials

Looking for clinical trials for Platinum Resistant? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Platinum Resistant trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Platinum Resistant clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 15 of 5 trials

Recruiting
Phase 1

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

Ovarian CancerEndometrial CancerOvarian Cancer Metastatic+4 more
Whitehawk Therapeutics, Inc.226 enrolled12 locationsNCT07444814
Recruiting
Phase 1

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

Endometrial CancerPlatinum Resistant Ovarian CancerPROC
Whitehawk Therapeutics, Inc.265 enrolled12 locationsNCT07470853
Recruiting
Phase 2

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

Advanced High-Grade Epithelial OvarianPrimary PeritonealFallopian Tube Cancers+2 more
AbbVie110 enrolled37 locationsNCT06682988
Recruiting
Phase 1

A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

Ovarian CancerPlatinum Resistant Ovarian CancerOvarian Cancer Recurrent
Outpace Bio, Inc.30 enrolled4 locationsNCT07030907
Recruiting
Phase 2

AKTRES study: A Biologic Study of the early effects and determinants of AKT inhibition using GSK2110183 alongside chemotherapy in patients with Platinum RESistant Adenocarcinoma of the ovary

Platinum Resistant Adenocarcinoma of the ovary
Royal Women's Hospital60 enrolled3 locationsACTRN12613000048785